LLY

906

-0.61%↓

JNJ

239.33

+1.21%↑

ABBV

205.95

-0.37%↓

NVS

149.44

-0.63%↓

MRK

118.95

+1.56%↑

LLY

906

-0.61%↓

JNJ

239.33

+1.21%↑

ABBV

205.95

-0.37%↓

NVS

149.44

-0.63%↓

MRK

118.95

+1.56%↑

LLY

906

-0.61%↓

JNJ

239.33

+1.21%↑

ABBV

205.95

-0.37%↓

NVS

149.44

-0.63%↓

MRK

118.95

+1.56%↑

LLY

906

-0.61%↓

JNJ

239.33

+1.21%↑

ABBV

205.95

-0.37%↓

NVS

149.44

-0.63%↓

MRK

118.95

+1.56%↑

LLY

906

-0.61%↓

JNJ

239.33

+1.21%↑

ABBV

205.95

-0.37%↓

NVS

149.44

-0.63%↓

MRK

118.95

+1.56%↑

Search

Twist Bioscience Corp

Open

SectorHealthcare

48.56 -3.02

Overview

Share price change

24h

Current

Min

47.42

Max

50.43

Key metrics

By Trading Economics

Income

-3.4M

-31M

Sales

4.7M

104M

Profit margin

-29.419

Employees

979

EBITDA

-3.2M

-24M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+6.91% upside

Dividends

By Dow Jones

Next Earnings

4 May 2026

Market Stats

By TradingEconomics

Market Cap

127M

2.7B

Previous open

51.58

Previous close

48.56

News Sentiment

By Acuity

50%

50%

167 / 350 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Twist Bioscience Corp Chart

Past performance is not a reliable indicator of future results.

Related News

25 Mar 2026, 20:20 UTC

Acquisitions, Mergers, Takeovers

Infosys Agrees to Acquire Stratus

25 Mar 2026, 23:58 UTC

Earnings

Guming Proposes 2025 Final Dividend of HK$0.50 >1364.HK

25 Mar 2026, 23:58 UTC

Earnings

Guming: Seek to Further Expand Coffee Product Line, Explore New Food Categories >1364.HK

25 Mar 2026, 23:57 UTC

Earnings

Guming: Aim to Expand Store Network in China, Evaluate Overseas Opportunities >1364.HK

25 Mar 2026, 23:57 UTC

Earnings

Guming Store Network Rose 37% on Year to 13,554 Stores as of Dec. 31, 2025 >1364.HK

25 Mar 2026, 23:56 UTC

Earnings

Guming 2025 Rev CNY12.91B Vs. CNY8.79B >1364.HK

25 Mar 2026, 23:56 UTC

Earnings

Guming 2025 Net CNY3.11B Vs. Net CNY1.48B >1364.HK

25 Mar 2026, 23:41 UTC

Market Talk

Nikkei May Trade Rangebound Amid Uncertainty Over U.S.-Iran Talks -- Market Talk

25 Mar 2026, 23:41 UTC

Earnings

These Stocks Are Today's Movers: Arm, Intel, AMD, Firefly Aerospace, Robinhood, JD.com, Sarepta, and More -- Barrons.com

25 Mar 2026, 23:34 UTC

Market Talk
Major News Events

Gold Declines on Possible Technical Correction -- Market Talk

25 Mar 2026, 22:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25 Mar 2026, 22:08 UTC

Market Talk

Synlait Milk's Outlook Depends on Dunsandel -- Market Talk

25 Mar 2026, 22:07 UTC

Earnings

China Mengniu Dairy: Weak Consumer Demand Weighed on Rev >2319.HK

25 Mar 2026, 22:07 UTC

Earnings

China Mengniu Dairy Plans Steady Increase in Dividends For Next Three Years >2319.HK

25 Mar 2026, 22:07 UTC

Earnings

China Mengniu Dairy: 2025 Net Supported by Absence of Impairment Provisions Made Last Year >2319.HK

25 Mar 2026, 22:07 UTC

Earnings

China Mengniu Dairy 2025 Rev CNY82.24B Vs. CNY88.67B >2319.HK

25 Mar 2026, 22:07 UTC

Earnings

China Mengniu Dairy 2025 Net CNY1.55B Vs. Net CNY104.51M >2319.HK

25 Mar 2026, 21:58 UTC

Market Talk

Amplitude Energy Oversold on Isabella-1 Well Disappointment -- Market Talk

25 Mar 2026, 21:37 UTC

Market Talk

Miran: AI and Deregulation Are Positive Supply Shocks To Economy -- Market Talk

25 Mar 2026, 21:14 UTC

Acquisitions, Mergers, Takeovers

St Barbara: Expects to Record Gain on Sale of Roughly A$500 Million Upon Completion

25 Mar 2026, 21:13 UTC

Acquisitions, Mergers, Takeovers

St Barbara: All Conditions Satisfied, Waived on Lingbao Deal

25 Mar 2026, 21:12 UTC

Acquisitions, Mergers, Takeovers

Closing M&A Deals Bring Opportunity. Janus Henderson and Other Stocks to Buy. -- Barrons.com

25 Mar 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

25 Mar 2026, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

25 Mar 2026, 20:33 UTC

Acquisitions, Mergers, Takeovers

KKR & Co.: Entered Agreement to Sell CoolIT Systems to Ecolab in Transaction Valued at $4.75B >KKR >KKR

25 Mar 2026, 20:31 UTC

Earnings

The SpaceX IPO Is Coming. Cathie Wood's Ark Venture and More Funds to Get in on the Action. -- Barrons.com

25 Mar 2026, 20:15 UTC

Acquisitions, Mergers, Takeovers

KKR Scores One of Its Best Bets With Sale of Data-Center Cooling Business -- WSJ

25 Mar 2026, 20:15 UTC

Acquisitions, Mergers, Takeovers

CoolIT Employees Set to Receive Average Payouts of $240,000, Executives Say -- WSJ

25 Mar 2026, 20:15 UTC

Acquisitions, Mergers, Takeovers

CoolIT Deal Ranks Among KKR's Top-4 Highest Earning Investments in Past 20 Years, Executives Say -- WSJ

25 Mar 2026, 20:15 UTC

Acquisitions, Mergers, Takeovers

KKR Set to Make 15x Investment From $4.75B Sale of CoolIT to Ecolab, Executives Say -- WSJ

Peer Comparison

Price change

Twist Bioscience Corp Forecast

Price Target

By TipRanks

6.91% upside

12 Months Forecast

Average 52 USD  6.91%

High 58 USD

Low 50 USD

Based on 6 Wall Street analysts offering 12 month price targets forTwist Bioscience Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

31.56 / 38.6884Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

167 / 350 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat